MX2023013859A - Polipeptidos modificados. - Google Patents
Polipeptidos modificados.Info
- Publication number
- MX2023013859A MX2023013859A MX2023013859A MX2023013859A MX2023013859A MX 2023013859 A MX2023013859 A MX 2023013859A MX 2023013859 A MX2023013859 A MX 2023013859A MX 2023013859 A MX2023013859 A MX 2023013859A MX 2023013859 A MX2023013859 A MX 2023013859A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- engineered polypeptides
- variants
- polypeptide
- engineered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
- C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192549P | 2021-05-24 | 2021-05-24 | |
| US202163265032P | 2021-12-06 | 2021-12-06 | |
| US202263266453P | 2022-01-05 | 2022-01-05 | |
| PCT/US2022/030556 WO2022251119A2 (en) | 2021-05-24 | 2022-05-23 | Engineered polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013859A true MX2023013859A (es) | 2024-02-15 |
Family
ID=82156443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013859A MX2023013859A (es) | 2021-05-24 | 2022-05-23 | Polipeptidos modificados. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250296986A1 (https=) |
| EP (1) | EP4347642A2 (https=) |
| JP (1) | JP2024521131A (https=) |
| KR (1) | KR20240035758A (https=) |
| AU (1) | AU2022280767A1 (https=) |
| BR (1) | BR112023024494A2 (https=) |
| CA (1) | CA3218489A1 (https=) |
| CL (1) | CL2023003455A1 (https=) |
| CO (1) | CO2023017754A2 (https=) |
| IL (1) | IL308509A (https=) |
| MX (1) | MX2023013859A (https=) |
| TW (1) | TW202306978A (https=) |
| WO (1) | WO2022251119A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022010912A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| CN116528897A (zh) | 2020-08-26 | 2023-08-01 | 旗舰开拓创新六世公司 | 靶向SARS-CoV-2的抗原结合分子 |
| TW202411246A (zh) | 2022-05-23 | 2024-03-16 | 美商維爾生物科技股份有限公司 | 經工程化之b型肝炎病毒中和抗體及其用途 |
| WO2023245078A1 (en) | 2022-06-15 | 2023-12-21 | Humabs Biomed Sa | Anti-parvovirus antibodies and uses thereof |
| WO2024006472A1 (en) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| CN119836435A (zh) | 2022-07-27 | 2025-04-15 | 胡默波斯生物医学公司 | 抗rsv和mpv副粘病毒的广泛中和抗体 |
| WO2024182781A1 (en) | 2023-03-02 | 2024-09-06 | Vir Biotechnology, Inc. | Coronavirus compositions and uses thereof |
| AU2024255423A1 (en) | 2023-04-10 | 2025-10-30 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| WO2025010424A1 (en) | 2023-07-06 | 2025-01-09 | Vir Biotechnology, Inc. | Antibodies against staphylococcus antigens and methods of using the same |
| WO2025015321A1 (en) | 2023-07-13 | 2025-01-16 | Vir Biotechnology, Inc. | Broadly neutralizing antibodies against rsv and mpv paramyxoviruses |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| ATE492562T1 (de) | 2003-09-24 | 2011-01-15 | Kyowa Hakko Kirin Co Ltd | Rekombinanter antikörper gegen humanen insulin- like growth factor |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| US20110081347A1 (en) * | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
| EP2640745B1 (en) | 2010-09-10 | 2018-11-07 | MedImmune Limited | Bivalent and bispecific anti-il6/anti-il23 antibodies |
| US9663581B2 (en) | 2012-04-25 | 2017-05-30 | Momenta Pharmaceuticals, Inc. | Modified glycoproteins |
| US10519251B2 (en) | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| EP3294774B1 (en) | 2015-05-13 | 2024-08-28 | Zumutor Biologics, Inc. | Afucosylated protein, cell expressing said protein and associated methods |
| WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
| AU2018334886B2 (en) | 2017-09-22 | 2025-06-26 | WuXi Biologics Ireland Limited | Novel bispecific polypeptide complexes |
| US20220298230A1 (en) * | 2019-06-11 | 2022-09-22 | The Rockefeller University | Antibodies and methods for treatment of viral infections |
-
2022
- 2022-05-23 KR KR1020237044483A patent/KR20240035758A/ko active Pending
- 2022-05-23 MX MX2023013859A patent/MX2023013859A/es unknown
- 2022-05-23 CA CA3218489A patent/CA3218489A1/en active Pending
- 2022-05-23 BR BR112023024494A patent/BR112023024494A2/pt unknown
- 2022-05-23 JP JP2023572165A patent/JP2024521131A/ja active Pending
- 2022-05-23 IL IL308509A patent/IL308509A/en unknown
- 2022-05-23 US US18/563,674 patent/US20250296986A1/en active Pending
- 2022-05-23 TW TW111119113A patent/TW202306978A/zh unknown
- 2022-05-23 AU AU2022280767A patent/AU2022280767A1/en active Pending
- 2022-05-23 WO PCT/US2022/030556 patent/WO2022251119A2/en not_active Ceased
- 2022-05-23 EP EP22732744.2A patent/EP4347642A2/en active Pending
-
2023
- 2023-11-21 CL CL2023003455A patent/CL2023003455A1/es unknown
- 2023-12-19 CO CONC2023/0017754A patent/CO2023017754A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202306978A (zh) | 2023-02-16 |
| BR112023024494A2 (pt) | 2024-02-06 |
| AU2022280767A1 (en) | 2024-01-18 |
| CO2023017754A2 (es) | 2024-05-10 |
| EP4347642A2 (en) | 2024-04-10 |
| WO2022251119A3 (en) | 2023-01-12 |
| CL2023003455A1 (es) | 2024-07-19 |
| CA3218489A1 (en) | 2022-12-01 |
| KR20240035758A (ko) | 2024-03-18 |
| WO2022251119A9 (en) | 2023-10-05 |
| IL308509A (en) | 2024-01-01 |
| JP2024521131A (ja) | 2024-05-28 |
| WO2022251119A2 (en) | 2022-12-01 |
| US20250296986A1 (en) | 2025-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013859A (es) | Polipeptidos modificados. | |
| MX2021003580A (es) | Nuevas inmunocitocinas para el tratamiento contra el cancer. | |
| PH12020552018A1 (en) | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies | |
| PH12021500051A1 (en) | Cd3 antigen binding fragments and compositions comprising same | |
| MX2023009995A (es) | Composiciones que incluyen adyuvantes de sbi y metodos para usarlos. | |
| MX2020007024A (es) | Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas. | |
| DK1709081T3 (da) | Fusionspolypeptider, der kan aktivere receptorer | |
| EA202191105A1 (ru) | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение | |
| PT2173381E (pt) | Polipéptidos que se ligam ao receptor fc, com funções efectivadoras modificadas | |
| WO2019241430A3 (en) | Antibody-oligonucleotide conjugates | |
| UA87106C2 (uk) | БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ РЕЦЕПТОР Nogo | |
| MX2023001595A (es) | Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas. | |
| UY38194A (es) | Proteína de fusión | |
| SG10201808158UA (en) | Site-specific glycoengineering of targeting moieties | |
| MX2021000263A (es) | Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma. | |
| WO2021252974A3 (en) | Collagen-targeted fusion proteins and antibodies | |
| WO2021003469A3 (en) | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same | |
| MX2019002178A (es) | Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74). | |
| WO2020127354A3 (en) | Polypeptides | |
| AU2021270786A8 (en) | Sample preparation for mass spectrometry | |
| DK1370284T3 (da) | Bakteriofag-medieret immunisering | |
| WO2003040311A3 (en) | Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4 | |
| MX2022003191A (es) | Terapias de combinacion con anticuerpos entpd2 y cd73. | |
| EP4435002A4 (en) | MODIFIED PROTEIN OR POLYPEPTIDE | |
| MX2022001219A (es) | Dominios variables humanos modificados. |